About Us.
At BillionToOne we strive to remove the fear of the unknown by providing molecular diagnostics that are accurate, fast, and accessible.
Our History
We have been carefully refining our process of precision diagnostics to create powerful molecular diagnostics since 2016.
BillionToOne Founded
In 2016 BillionToOne was founded by lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut mauris dui, egestas at leo a, luctus porta dui. Etiam a lectus vitae eros tristique sollicitudin non quis orci. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas.
Received a National Institutes of Health grant for the first single-gene NIPT clinical study with Baylor University
In 2018 lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut mauris dui, egestas at leo a, luctus porta dui. Etiam a lectus vitae eros tristique sollicitudin non quis orci. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas.
Launched UNITY aneuploidy and RhD tests
In 2022 lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut mauris dui, egestas at leo a, luctus porta dui. Etiam a lectus vitae eros tristique sollicitudin non quis orci. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas.
Published single-gene NIPT health economics study in Journal of Health Economics
In 2022 lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut mauris dui, egestas at leo a, luctus porta dui. Etiam a lectus vitae eros tristique sollicitudin non quis orci. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas.
Launched UNITY fetal antigen NIPT for alloimmunized pregnant patients
Our results are thoughtfully designed. They will provide a summary, detailed results, as well as next steps. Licensed genetic counselors are here to answer your questions, usually within 1 business day.
Who We Are.
We’re a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. We work to improve disease detection by counting molecules with our proprietary molecular counting platform. We place patients at the forefront of everything we do. We are currently applying our proprietary technology to non-invasive prenatal screening and liquid biopsy.
Meet Our National Medical Advisor Team Behind Our Mission.
Gain deeper insights into the exceptional expertise of the medical advisors who play a pivotal role in shaping our innovations.
Providers
